No Detail Found!

Hematological toxicity assessment in breast cancer patients receiving paclitaxel: Retrospective study and single center experience

Author(s)
Shad Adil Noori Qaiwan International University, Faculty of Pharmacy, Al Sulaymaniyah, Iraq;Near East University, Faculty of Pharmacy, Clinical Pharmacy Department, Nicosia, Turkey
Lanja Ibrahim Saeed Clinical Pharmacy Department, Hiwa Cancer Hospital,Sulaymaniyah,Iraq
Abstract
Hematological toxicity is a predominant concern encountered during cancer treatment. Regular blood tests and follow-up are crucial for cancer patients. The objective of this study was to evaluate and compare the hematological toxicities seen by breast cancer patients who were administered paclitaxel during treatment cycles. An observational retrospective study was conducted at the Oncology Clinic at Hiwa Hospital in The Kurdistan Region of Iraq between January 2021 and May 2022. Among the 141 breast cancer patients included in the study, 74 patients did not receive granulocyte-colony stimulating factor prior to the baseline, while 67 patients did receive it. A significant statistical difference was observed in the White Blood Cells parameter among cancer patients who did not receive granulocytecolony stimulating factor before the baseline when comparing the 2nd cycle to the 3rd cycle of Paclitaxel treatment (Pvalue = 0.001). Statistically significant differences were seen between the Baseline and 1st Cycle, Baseline and 2nd Cycle and Baseline and 3rd Cycle (P-value = 0.0312, 0.031 and 0.031, respectively) in grade 1 neutropenia among the 67 patients who received granulocyte-colony stimulating factor prior to the baseline. This study determined that anemia is a frequently observed hematological side effect of chemotherapy in breast cancer patients who are undergoing treatment with paclitaxel, followed by grade 1 neutropenia.
Publication Details
Page(s) 1229-1238
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 37, Issue: 6, Year: 2024

Request the full text from PASTIC

Keywords
cancer patients, Breast Cancer, Paclitaxel, Hiwa hospital, Hematological toxicity
References
Alalawy AI .2024 .Key genes and molecular mechanisms related to paclitaxel resistance. Cancer Cell Int, 24(1) : 244.
Al-Hashimi MMY .2021 .Trends in breast cancer incidence in Iraq during the period 2000-2019. , 22(12) : 3889-3896.
Alsanad SM,Howard RL,Williamson EM RL .2016 .An assessment of the impact of herb-drug combinations used by cancer patients. BMC Complement. Altern. Med, 16(1) : 393.
Basak D,Arrighi S,Darwiche Y,Deb S Y .2021 .Comparison of anticancer drug toxicities: Paradigm shift in adverse effect profile. Life, 12(1) : 48.
Daniel D and Crawford J .2006 .Myelotoxicity from chemotherapy. Seminars in Oncology, 33(1) : 74-85.
Feliu J,Heredia-Soto V,Gironés R,Jimenez-Munarriz B,Saldana J,Guillén-Ponce C,Molina-Garrido MJ C .2020 .Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clin. Transl, 22 : 457-467.
Havrilesky LJ,Garfield CF,Barnett JC,Cohn DE JC .2012 .Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer. Gynecol. Oncol., 125(3) : 631-634.
Khalifa MF,Pharm MF .2022 .Epidemiology of breast cancer in Baghdad City 2018. , : 1452-1456.
Ludwig H,Van Belle S,Barrett-Lee P,Birgegård G,Bokemeyer C,Gascón P,Schrijvers D .2004 .The European Cancer Anaemia Survey (ECAS): A large multinational prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur. J. Cancer, 40(15) : 2293-2306.
Nardin S,Mora E,Varughese FM,D'Avanzo F,Vachanaram AR,Rossi V,Gennari A .2020 .Breast cancer survivorship, quality of life and late toxicities. Front. Oncol., 10 : 864.
Othman RT,Abdulljabar R,Saeed A,Sadiq S,Kittani HM,Mohammed SA,Hussein NR .2011 .Cancer incidence rates in the Kurdistan Region/Iraq from. Asian Pac. J. Cancer Prev, 12(5) : 1261-64.
Pizzo PA,Poplack DG .2015 .. Principles and Practice of Pediatric Oncology. Lippincott Williams & Wilkins., : .
Salih K .1995 .Anfal: The Kurdish genocide in Iraq. , 4(2) : 24-39.
Schelenz S,Giles D,Abdallah S D .2012 .Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. , 23(7) : 1889-1893.
Takahashi S,Takei Y,Tamura K,Taneichi A,Takahashi Y,Yoshiba T,Fujiwara H T .2022 .Response to and toxicity of weekly paclitaxel and carboplatin in patients with stage IIIC-IV ovarian cancer and poor general condition. Mol. Clin. Oncol., 16(1) : 1-7.
Testart-Paillet D,Girard P,You B,Freyer G,Pobel C,Tranchand B C .2007 .Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Crit. Rev. Oncol. Hematol, 63(1) : 1-11.
.2023 .National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5. US Department of Health and Human Services, : .
Vogel CL,Wojtukiewicz MZ,Carroll RR,Tjulandin SA,Barajas-Figueroa LJ,Wiens BL,Schwartzberg LS .2005 .First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J. Clin. Oncol., 23(6) : 1178-1184.
World Health .2013 .1 million new cases in 2012. Latest world cancer statistics: Global cancer burden rises to 14, : .
0

Citations

0

Downloads

61

Views